Figure 3.
C35-PP accumulation increases bacitracin sensitivity. Bacitracin disk diffusion assays of (A) WT (168), ΔsqhC (HB13358), ΔytpB (HB13321), and ΔsqhC ΔytpB (HB13360) strains on MH medium; (B) WT (168), ΔhepT (HB13447), ΔytpB (HB13321), and ΔhepT ΔytpB (HB13448) strains on MH media containing 10 µg ml−1 menaquinone; (C) WT (168) and ΔytpB (HB13321) strains on MH containing either no supplement, 100 µg ml−1 tryptophan, 10 µg ml−1 1,4-dihydroxy-2-naphthoic acid (DHNA), or 10 µg ml−1 menaquinone; (D) WT (168), Pspac(hy)-hepSmenHhepT (HB13398), ΔytpB (HB13321), and Pspac(hy)-hepSmenHhepT ΔytpB (HB13402) strains on MH medium containing 1 mM IPTG; and (E) WT (168), ΔmenA (HB13438), ΔytpB (HB13321), and ΔmenA ΔytpB (HB13439) strains on MH media containing 10 µg ml−1 menaquinone.